Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
作者： James A Eastham , William K Kelly , Gary D Grossfeld , Eric J Small
DOI: 10.1016/J.UROLOGY.2003.09.052
关键词: Transurethral resection of the prostate 、 Urology 、 Neoadjuvant therapy 、 Estramustine 、 Prostatectomy 、 Localized disease 、 Surgery 、 Docetaxel 、 Tolerability 、 Prostate cancer 、 Medicine
摘要: … The feasibility of estramustine-based chemotherapy before RP has been demonstrated in 3 … 4 cycles of chemotherapy, and 1 patient each completed 2 or 6 cycles of chemotherapy. …
elsevier.com
sci-hub.se 参考文章(43)
F Nathan, C Khater, N Haas, M Cornfield, B Giantonio, R Greenberg, L Gomella, S Litwin, E Ross, S Roethke, C McAleer, G R Hudes, Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. ,vol. 15, pp. 3156- 3163 ,(1997) , 10.1200/JCO.1997.15.9.3156
Joanna B. Madalinska, Marie-Louise Essink-Bot, Harry J. de Koning, Wim J. Kirkels, Paul J. van der Maas, Fritz H. Schröder, Health-Related Quality-of-Life Effects of Radical Prostatectomy and Primary Radiotherapy for Screen-Detected or Clinically Diagnosed Localized Prostate Cancer Journal of Clinical Oncology. ,vol. 19, pp. 1619- 1628 ,(2001) , 10.1200/JCO.2001.19.6.1619
Philip W. Kantoff, Susan Halabi, Mark Conaway, Joel Picus, Jeffrey Kirshner, Vera Hars, Donald Trump, Eric P. Winer, Nicholas J. Vogelzang, Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study Journal of Clinical Oncology. ,vol. 17, pp. 2506- 2513 ,(1999) , 10.1200/JCO.1999.17.8.2506
D.M. Savarese, S. Halabi, V. Hars, W.L. Akerley, M-E Taplin, P.A. Godley, A. Hussain, E.J. Small, N.J. Vogelzang, Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780 Journal of Clinical Oncology. ,vol. 19, pp. 2509- 2516 ,(2001) , 10.1200/JCO.2001.19.9.2509
I F Tannock, D Osoba, M R Stockler, D S Ernst, A J Neville, M J Moore, G R Armitage, J J Wilson, P M Venner, C M Coppin, K C Murphy, Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of Clinical Oncology. ,vol. 14, pp. 1756- 1764 ,(1996) , 10.1200/JCO.1996.14.6.1756
M. W. Kattan, Postoperative nomogram for 12-year sarcoma-specific death Journal of Clinical Oncology. ,vol. 20, pp. 791- 796 ,(2002) , 10.1200/JCO.20.3.791
Markus Graefen, Pierre I Karakiewicz, Ilias Cagiannos, Peter G Hammerer, Alexander Haese, Jüri Palisaar, Salvador Fernandez, Jochen Noldus, Andreas Erbersdobler, Hartwig Huland, Peter T Scardino, Michael W Kattan, None, A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urologic Oncology-seminars and Original Investigations. ,vol. 7, pp. 141- 146 ,(2002) , 10.1016/S1078-1439(02)00177-1
Wim P.J. Witjes, Claude C. Schulman, Frans M.J. Debruyne, Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma Urology. ,vol. 49, pp. 65- 69 ,(1997) , 10.1016/S0090-4295(97)00171-4
Beryl Hartley-Asp, Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. The Prostate. ,vol. 5, pp. 93- 100 ,(1984) , 10.1002/PROS.2990050109
M E Stearns, M Wang, K D Tew, L I Binder, Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells Journal of Cell Biology. ,vol. 107, pp. 2647- 2656 ,(1988) , 10.1083/JCB.107.6.2647